Indirect antitumor effects of bisphosphonates on prostatic LNCaP cells co-cultured with bone cells

Anticancer Res. 2009 Apr;29(4):1089-94.

Abstract

Bisphosphonates are strong inhibitors of osteoclastic bone resorption in both benign and malignant bone diseases. The nitrogen-containing bisphosphonates (N-BPs) have strong cytotoxicity via inhibition of protein prenylation in the mevalonate pathway, and also demonstrate direct cytostatic and proapoptotic effects on prostate cancer cells. We confirmed the usefulness of a co-culture system comprised of prostatic LNCaP cells, ST2 cells (mouse-derived osteoblasts) and MLC-6 cells (mouse-derived osteoclasts) in vitro. N-BPs (pamidronate and zoledronic acid) inhibited both androgen receptor transactivation and tumor cell proliferation by suppressing the activities of both osteoclasts and osteoblasts with low-dose exposure. This indirect inhibition of prostate cancer cells via bone cells could be beneficial in treating prostate cancer patients with bone metastases.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antineoplastic Agents / pharmacology
  • Bone Density Conservation Agents / pharmacology
  • Cell Proliferation / drug effects
  • Coculture Techniques
  • Diphosphonates / pharmacology*
  • Humans
  • Imidazoles / pharmacology*
  • Luciferases / metabolism
  • Male
  • Mice
  • Osteoblasts / cytology
  • Osteoclasts / cytology
  • Pamidronate
  • Prostatic Neoplasms / drug therapy*
  • Prostatic Neoplasms / metabolism
  • Prostatic Neoplasms / pathology
  • RNA, Messenger / genetics
  • RNA, Messenger / metabolism
  • Receptors, Androgen / genetics
  • Receptors, Androgen / metabolism
  • Reverse Transcriptase Polymerase Chain Reaction
  • Transcriptional Activation
  • Tumor Cells, Cultured
  • Zoledronic Acid

Substances

  • Antineoplastic Agents
  • Bone Density Conservation Agents
  • Diphosphonates
  • Imidazoles
  • RNA, Messenger
  • Receptors, Androgen
  • Zoledronic Acid
  • Luciferases
  • Pamidronate